Jean-Pierre Enguent, Vice President of R&DSS at SEALSQ Corp, filed a Form 4 on November 3, 2026, disclosing the exercise of employee stock options and the sale of 35,000 ordinary shares on November 2-3, 2026, pursuant to a Rule 10b5-1 trading plan.

Key Highlights

  • Role: Jean-Pierre Enguent is identified as Vice President, R&DSS of SEALSQ Corp (NASDAQ:LAES).
  • Options exercised: Enguent exercised a total of 35,000 Employee Stock Option Plan shares on November 2, 2026, at an exercise price of $0.01 per share.
  • Shares sold: 35,000 ordinary shares were sold on November 3, 2026, at a weighted average price of $1.3808, in multiple transactions ranging from $1.3615 to $1.412 per share.
  • Resulting ownership: Following all reported transactions, Enguent's direct beneficial ownership of ordinary shares stands at 0.
  • New options granted: 50,000 Employee Stock Option Plan options were acquired on November 2, 2026, at an exercise price of $0.01, exercisable through April 30, 2032, with 30,000 remaining after the exercise reported.
  • 10b5-1 plan: The sales and option exercises were effected pursuant to a Rule 10b5-1 trading plan adopted by Enguent on October 13, 2025.

Enguent's Option Exercises and Share Sale at SEALSQ Corp

According to the filing, Jean-Pierre Enguent exercised two tranches of Employee Stock Option Plan rights on November 2, 2026. The first tranche covered 15,000 ordinary shares at $0.01, bringing his direct holdings to 15,000 shares. The second tranche covered an additional 20,000 ordinary shares, also at $0.01, raising his direct holdings to 35,000 shares. Both exercises are reported as transaction code "M" and were carried out under a Rule 10b5-1 plan adopted on October 13, 2025, the filing states.

The filing further discloses that on November 3, 2026, Enguent sold all 35,000 ordinary shares under transaction code "S" at a weighted average price of $1.3808. The shares were sold in multiple transactions at prices ranging from $1.3615 to $1.412, inclusive. Following this sale, the filing reports Enguent's direct beneficial ownership of ordinary shares as 0. The reporting person has undertaken to provide full information on the number of shares sold at each separate price upon request, according to the filing.

Separately, the filing records the acquisition of 50,000 new Employee Stock Option Plan options on November 2, 2026, with an exercise price of $0.01 and an expiration date of April 30, 2032. After the exercise of 20,000 of these options on the same date, 30,000 remain. The filing was signed by John O'Hara as Attorney-in-Fact on November 3, 2026, and the form indicates that a Rule 10b5-1(c) box has been checked to reflect that covered transactions were made pursuant to a written plan.

What Was Disclosed

Jean-Pierre Enguent, Vice President of R&DSS at SEALSQ Corp, disclosed the exercise of 35,000 employee stock options and the sale of 35,000 ordinary shares, reducing his direct share ownership to zero, all under a pre-established Rule 10b5-1 trading plan.